WO2023079366 - METHODS AND COMPOSITIONS FOR TREATING MICROGLIAL DYSFUNCTION AND IMPROVING METABOLIC DYSFUNCTION
National phase entry:
Publication Number
WO/2023/079366
Publication Date
11.05.2023
International Application No.
PCT/IB2022/000668
International Filing Date
08.11.2022
Title **
[English]
METHODS AND COMPOSITIONS FOR TREATING MICROGLIAL DYSFUNCTION AND IMPROVING METABOLIC DYSFUNCTION
[French]
PROCÉDÉS ET COMPOSITIONS POUR TRAITER UN DYSFONCTIONNEMENT MICROGLIAL ET AMÉLIORER UN DYSFONCTIONNEMENT MÉTABOLIQUE
Applicants **
ULTIMATE MEDICINE AG
C/o CHFL AG, Heerenwiesen 5
8051 Zurich, CH
ALBERT-LUDWIGS-UNIVERSITAT FREIBURG
Fahnenbergplatz
79085 Freibury Im Breisgau, DE
Inventors
SZALAY, Antal
Stettbachstrasse 127f
8051 Zurich, CH
BLANK, Thomas
Zartener Str. 4
79199 Kirchzarten, DE
Priority Data
63/276,996
08.11.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2354 | |
| EPO | Filing, Examination | 12421 | |
| Japan | Filing | 588 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 10560 |
Total: 26497 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure relates to methods and composition for treating or decreasing the rate of development of cognitive impairment, a neurodegen erative disease, or neuronal dysfunction in a. subject in need thereof. The methods include administration to the subject of a gut barrier function enhancer and/or an agent for reducing or eliminating gut microbiota dysfunction. The disclosure also provides methods for identifying such a subject.[French]
La présente invention concerne des procédés et une composition pour traiter ou diminuer le taux de développement d'une déficience cognitive, d'une maladie neurodégénérative ou d'un dysfonctionnement neuronal chez un sujet en ayant besoin. Les procédés comprennent l'administration au sujet d'un activateur de la fonction barrière intestinale et/ou d'un agent pour réduire ou éliminer un dysfonctionnement du microbiote intestinal. L'invention concerne également des procédés d'identification d'un tel sujet.